Period of time： 2013年12期
Publisher： Future Science
Founded in： 2011
Total resources： 8
ISSN： 2041-6792
Subject： R Medicine and Health
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Clinical Investigation,volume 3,issue 12
Menu
What does the future hold for uveal melanoma, a historically untreatable disease?
By Shoushtari Alexander N,Carvajal Richard D in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.
Access to resources
Recommend
A close look at trachoma control and the challenges that district programs pose
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.By Aboul-Fotouh Hebah,Baker Lauren A,Jackson Michelle Lucero,Cockerell Clay J in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.Developing a consortium for ALS clinical research: the Canadian ALS Research Network
By Zinman Lorne,Genge Angela,Figlewicz Denise A in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.Beyond Jadad: some essential features in trial quality
By Alperson Sunny Y,Berger Vance W in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.By Williams Loretta A,Yucel Emre,Cortes Jorge E,Cleeland Charles S in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
By Spagnolo Paolo,Luppi Fabrizio in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.Surrogate end points: when should they be used?
By Molenberghs Geert,Abad Ariel Alonso,van der Elst Wim,Burzykowski Tomasz,Buyse Marc in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.Adverse event monitoring in oncology clinical trials
By Russell Jeffery S,Colevas A Dimitrios in (2013)
Clinical Investigation,volume 3,issue 12 , Vol. 3, Iss. 12, 2013-12 , pp.
Previous
Next